Moderna (MRNA) has potential for growth with diversified pipeline and strong financial position.

From Yahoo Finance: 2025-06-24 16:27:00

Moderna, Inc. (MRNA) has seen its stock drop significantly from pandemic highs, but a bullish thesis highlights its vast pipeline of 45 candidates, $8 billion in cash, and potential recurring COVID vaccine revenue. Management aims for profitability by 2028 without additional capital. The market may undervalue MRNA’s potential, offering a contrarian opportunity for long-term investors.

Despite recent skepticism, Moderna (MRNA) remains resilient with a diversified pipeline and strong financial position. Near-term challenges include market competition, reduced COVID vaccination rates, and political volatility. However, upcoming catalysts and new manufacturing facilities could drive future growth. Management predicts profitability by 2028 without additional capital.

Hedge funds have reduced their holdings of Moderna, Inc. (MRNA), with 38 portfolios holding the stock at the end of the first quarter. While MRNA presents investment potential, other AI stocks may offer greater returns with less downside risk. Investors seeking opportunities in the AI sector may find more promising options than MRNA.



Read more at Yahoo Finance: Moderna, Inc. (MRNA): A Bull Case Theory